Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerStatistical controversies in clinical research: long-term follow-up of clinical trials in cancerProstate cancer biomarkers: Are we hitting the mark?How Precisely Can Prostate Cancer Be Managed?Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other CancersImproving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling StudyActive surveillance for intermediate-risk prostate cancerA novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.Active Surveillance for Intermediate Risk Prostate Cancer.Clinical Utility of Biomarkers in Localized Prostate Cancer.Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.Tissue-based biomarkers in prostate cancer.Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer.Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.The Use of Biomarkers in Prostate Cancer Screening and Treatment.Prognosis: Proportionate response.[Molecular biomarkers and prognostic factors for prostate cancer].Emerging biomarkers in the diagnosis of prostate cancer.Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively.A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.Genomic biomarkers in prostate cancerProlaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology AssessmentImproving risk stratification in a community-based African American population using cell cycle progression score
P2860
Q26738703-5181221F-441D-4095-AE7F-B01211885C51Q26782494-476C273D-8DFB-4712-AEAE-7AF867CA870FQ28071654-0D43ECC3-FA52-4D11-8699-7279D1496E75Q28078942-6532F219-64DE-4E93-98C7-B6AA1CF9D502Q33624448-6AA161B8-7D80-458F-8E0E-9271F249581CQ36092572-B61F23A6-4A98-4D72-BB1B-6C41B52DEE45Q37636975-4CEE4F9D-EB8B-4565-AD8D-A222747E0268Q37687723-72410C0A-D5E2-43A0-B2DF-82BF089009ADQ38610286-6802E201-482C-4718-B19B-87C3CAC05F8DQ38627996-7A45CA1A-9132-49B3-9C05-CF4070AB199EQ38792354-E10B472C-FAF4-4C86-B2CD-42C7873CBFC8Q38841717-6BD3E9EA-A579-466A-8202-A3845CC4729BQ39108592-F77D4CC7-EFE3-49DE-B1C6-29CD1C752421Q40204742-74FDA017-08E0-4B0E-B26C-29276EF0BAC9Q47144748-CDAFB998-5D32-4C18-A626-821B13975075Q47215343-B08BEE1A-40B8-47C3-A9F8-0F3EA68A0927Q47894036-94449B94-2E65-494F-B221-BA90A0F61A68Q52689045-8ACD0BCA-CB1A-47E7-A8A3-5FDCBC3E8594Q53242580-7F4E1AFA-C336-44AE-A7FF-ADBF300366CBQ53251387-5C39F836-1BD3-46DB-8E04-8ADAE2A2D85BQ54964875-85BFC8A4-C292-47AC-87EA-E1E399FC512AQ55095968-E0477646-9BF6-4539-93C0-4B24A81A0BB9Q55517990-E375B9B9-6290-4E3B-ADE8-F5320DEDB470Q57112354-DFEDD25F-F1D5-46E3-B643-4AD71D009826Q57117462-E7F5684D-C07C-46FE-AABB-9C340EC25BD2Q58562156-19895E80-4E9E-4F43-9DC2-BAEF63F870A5
P2860
Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Validation of an RNA cell cycl ...... y managed needle biopsy cohort
@ast
Validation of an RNA cell cycl ...... y managed needle biopsy cohort
@en
type
label
Validation of an RNA cell cycl ...... y managed needle biopsy cohort
@ast
Validation of an RNA cell cycl ...... y managed needle biopsy cohort
@en
prefLabel
Validation of an RNA cell cycl ...... y managed needle biopsy cohort
@ast
Validation of an RNA cell cycl ...... y managed needle biopsy cohort
@en
P2093
P2860
P356
P1476
Validation of an RNA cell cycl ...... y managed needle biopsy cohort
@en
P2093
D Greenberg
J S Lanchbury
P Scardino
P2860
P2888
P304
P356
10.1038/BJC.2015.223
P407
P577
2015-06-23T00:00:00Z